Managing multiple Claude Code projects doesn't have to be chaotic. My iTerm2 setup dramatically reduces friction in my daily ...

Sigrid Jin woke up to chaos and shipped "Claw Code" by breakfast. Here's everything it taught the world.

Landmark, third-party research strengthens evidence of long-term impact beyond a single Girls on the Run season. CHARLOTTE, NC, UNITED STATES, March 25, 2026 ...

The drumbeat for the diminishing prospects of the first-run syndication business has been growing louder over the past few years amid a shrinking marketplace. Now, NBCUniversal has become the first ...

When students talk about the ability to take Running Start courses during the summer, they don’t talk about credits; they talk about opportunity. For one high school student, enrolling in a summer ...

In uncertain times, focus on your strengths and use AI to deepen customer trust, not chase distractions. Data-driven decisions and transparent communication help businesses stay resilient when ...

Social Security, which provides benefits to about 70 million Americans, could run out of money sooner than expected, according to a new report from the Congressional Budget Office. The Old-Age and ...

The ruling by the Oregon Land Use Board of Appeals favors the city’s plans to build a plant to filter water from the forested watershed. A demonstration of operations at a pilot water treatment plant, ...

From building personalized workout plans to answering form questions, AI tools like ChatGPT are quickly becoming fixtures in the gym—and it’s clear as to why. “ ChatGPT can harness the power of the ...

Fullerton has launched its new city-operated ambulance transportation program. Under the model, fire personnel will manage the full emergency response, from initial patient contact to transport to a ...

Blue Origin has “paused” its New Shepard program for the next two years, a move that likely signals a permanent end to the suborbital space tourism initiative. The small rocket and capsule have been ...

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.